NovoCure Ltd

NVCR

Explore Our Financial Data > Companies > NovoCure Ltd

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	NVCR
CIK	0001645113
SIC	3841
Sector	Manufacturing
Industry Category	Medical Equipment
Industry Group	Surgical, Medical, And Dental Instruments And Supplies

Contact

Address	NO. 4 THE FORUM, GRENVILLE STREET, ST. HELIER, Y9, JE2 4UF
Website	novocure.com
Phone	44 (0)15 3475 6700
CEO	Asaf Danziger
Employees	1,320

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$630.16 million
Pre-Tax Income	$-142.06 million
Net Income	$-170.95 million
Net Income to Common	$-170.95 million
EPS	$-1.56

View All

Balance Sheet

Cash	$149.62 million
Assets	$1.25 billion
Liabilities	$896.43 million
Common Equity	$349.44 million
Liabilities & Equity	$1.25 billion

View All

Cash Flow Statement

Net Income	$-170.95 million
Cash From Operating Activities	$-44.68 million
Cash From Investing Activities	$17.50 million
Cash From Financing Activities	$10.42 million
Change in Cash	$-16.31 million

View All

Calculations

NOPAT	$-120.95 million
EBITDA	$-186.97 million
Price to Earnings	N/A
Price to Book	$3.62
ROE	-48.07%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

NovoCure Second Quarter 2025 Earnings: Beats Expectations

NovoCure ( NASDAQ:NVCR ) Second Quarter 2025 Results Key Financial Results Revenue: US$158.8m (up 5.6% from 2Q 2024...

Article Link

NovoCure: Q2 Earnings Snapshot

ST. HELIER, Jersey (AP) — NovoCure Ltd. (NVCR) on Thursday reported a loss of $40.1 million in its second quarter. On a per-share basis, the St. Helier, Jersey-based company said it had a loss of 36 cents.

Article Link

NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for NovoCure (NVCR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Article Link

NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of +7.69% and +3.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Article Link

Novocure Reports Second Quarter 2025 Financial Results

BAAR, Switzerland, July 24, 2025--Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).

Article Link